Guilin Sanjin Pharmaceutical Co., Ltd. (SHE:002275)
12.13
-0.38 (-3.04%)
Nov 20, 2026, 3:04 PM CST
SHE:002275 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 7,127 | 8,285 | 8,866 | 8,514 | 7,570 | 9,728 | |
Market Cap Growth | -18.48% | -6.56% | 4.14% | 12.46% | -22.18% | 13.41% |
Enterprise Value | 5,907 | 7,206 | 7,964 | 7,554 | 6,484 | 8,505 |
Last Close Price | 12.13 | 13.66 | 14.08 | 13.01 | 11.44 | 13.68 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 16.84 | 19.13 | 17.00 | 20.21 | 22.97 | 28.30 |
Forward PE | - | 17.06 | 18.63 | 15.39 | 16.92 | 16.92 |
PS Ratio | 3.52 | 4.05 | 4.04 | 3.92 | 3.86 | 5.59 |
PB Ratio | 2.12 | 2.60 | 2.95 | 3.02 | 2.69 | 3.43 |
P/TBV Ratio | 2.21 | 2.72 | 3.10 | 3.20 | 2.87 | 3.66 |
P/FCF Ratio | 12.27 | 13.34 | 17.52 | 18.01 | 16.23 | 36.55 |
P/OCF Ratio | 10.55 | 11.70 | 15.07 | 15.50 | 14.32 | 23.71 |
PEG Ratio | - | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.91 | 3.52 | 3.63 | 3.48 | 3.31 | 4.88 |
EV/EBITDA Ratio | 10.00 | 12.05 | 13.73 | 13.13 | 15.73 | 20.59 |
EV/EBIT Ratio | 11.75 | 14.01 | 16.41 | 16.41 | 20.54 | 26.06 |
EV/FCF Ratio | 10.17 | 11.60 | 15.74 | 15.98 | 13.90 | 31.95 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.11 | 0.16 | 0.20 | 0.19 | 0.17 | 0.21 |
Debt / EBITDA Ratio | 0.60 | 0.84 | 1.00 | 0.92 | 1.08 | 1.41 |
Debt / FCF Ratio | 0.61 | 0.83 | 1.17 | 1.12 | 1.00 | 2.29 |
Net Debt / Equity Ratio | -0.36 | -0.38 | -0.36 | -0.31 | -0.34 | -0.38 |
Net Debt / EBITDA Ratio | -2.11 | -2.02 | -1.87 | -1.52 | -2.33 | -2.64 |
Net Debt / FCF Ratio | -2.10 | -1.94 | -2.14 | -1.86 | -2.06 | -4.10 |
Asset Turnover | 0.48 | 0.48 | 0.54 | 0.55 | 0.49 | 0.44 |
Inventory Turnover | 2.28 | 2.47 | 2.63 | 2.41 | 2.17 | 1.91 |
Quick Ratio | 4.11 | 2.69 | 2.33 | 2.09 | 2.39 | 2.56 |
Current Ratio | 4.70 | 3.01 | 2.58 | 2.46 | 2.71 | 2.96 |
Return on Equity (ROE) | 12.77% | 13.97% | 17.90% | 14.96% | 11.66% | 11.86% |
Return on Assets (ROA) | 7.41% | 7.57% | 7.43% | 7.28% | 4.90% | 5.11% |
Return on Invested Capital (ROIC) | 18.99% | 21.21% | 20.33% | 19.74% | 12.95% | 15.51% |
Return on Capital Employed (ROCE) | 13.60% | 14.80% | 15.00% | 15.10% | 10.10% | 10.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 5.94% | 5.23% | 5.88% | 4.95% | 4.35% | 3.53% |
FCF Yield | 8.15% | 7.50% | 5.71% | 5.55% | 6.16% | 2.74% |
Dividend Yield | 4.12% | 3.55% | 3.98% | 4.14% | 6.21% | 5.32% |
Payout Ratio | 72.19% | 78.74% | 64.45% | 101.54% | 173.24% | 132.00% |
Buyback Yield / Dilution | -0.93% | 0.11% | -0.15% | 0.56% | -2.72% | 0.74% |
Total Shareholder Return | 3.19% | 3.66% | 3.83% | 4.70% | 3.49% | 6.06% |